Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Eli Lilly
Eli Lilly
After First Approval, Experts Point to Barriers in Cell Therapy for Type 1 Diabetes
BioSpace
Thu, 07/13/23 - 10:11 am
CellTrans
Lantidra
type 1 diabetes
cell therapy
Eli Lilly
Siglion Therapeutics
Pharma finds a way to gain weight
EP Vantage
Thu, 07/13/23 - 09:49 am
obesity
Eli Lilly
Novo Nordisk
Wegovy
Mounjaro
Biopharma’s green shoots thriving in summer sun as deal activity returns
Fierce Biotech
Tue, 07/11/23 - 11:18 pm
M&A
Eli Lilly
Siglion Therapeutics
DiCE Therapeutics
GSK
Bellus Health
Biopharma buyouts bounce back
EP Vantage
Wed, 07/5/23 - 10:17 am
M&A
Amgen
Astellas
Eli Lilly
GSK
Horizon Therapeutics
Merck
Novartis
Pfizer
Seagen
Pfizer Just Canned One of Its Ozempic Killers. What's Next?
Motley Fool
Mon, 07/3/23 - 10:37 am
Pfizer
obesity
lotiglipron
danuglipron
Novo Nordisk
Eli Lilly
Ozempic
Mounjaro
Lilly to Buy European ADC Player Emergence Therapeutics
BioSpace
Fri, 06/30/23 - 10:20 am
Eli Lilly
M&A
Emergence Therapeutics
antibody-drug conjugate
oncology
Eli Lilly to buy Sigilon Therapeutics to expand diabetes treatments
Yahoo/Reuters
Thu, 06/29/23 - 11:56 am
Eli Lilly
M&A
Sigilon
cell therapy
diabetes
ADA 2023 – Lilly unveils its triple threat
EP Vantage
Wed, 06/28/23 - 09:57 am
Eli Lilly
Novo Nordisk
retatrutide
Wegovy
Mounjaro
obesity
clinical trials
Lilly forks over $2.4M to settle federal agency's age discrimination lawsuit
Fierce Pharma
Tue, 06/27/23 - 10:39 pm
Eli Lilly
age discrimination
legal
Lilly links oral obesity drug to 15% weight loss, setting bar for Pfizer in blockbuster battle
Fierce Biotech
Mon, 06/26/23 - 10:00 am
Eli Lilly
obesity
orforglipron
Pfizer
Novo Nordisk
Mounjaro
Is Eli Lilly's Dice Therapeutics Acquisition a Needle-Moving Event?
Motley Fool
Wed, 06/21/23 - 11:02 pm
Eli Lilly
DiCE Therapeutics
M&A
ADA 2023 preview – Lilly’s oral obesity data leave room for Pfizer
EP Vantage
Wed, 06/21/23 - 10:38 am
ADA
Eli Lilly
Pfizer
diabetes
obesity
orforglipron
danuglipron
lotiglipron
FDA Approves New Class of Medicines to Treat Pediatric Type 2 Diabetes
Benzinga
Tue, 06/20/23 - 09:46 pm
Eli Lilly
Boehringer Ingelheim
Jardiance
Synjardy
type 2 diabetes
pediatric
FDA
Lilly makes fresh bet on IL-17 with $2.4B acquisition of Dice Therapeutics
Fierce Biotech
Tue, 06/20/23 - 11:31 am
Eli Lilly
M&A
DiCE Therapeutics
autoimmune disease
Lilly’s Migraine Drug Emgality Fails to Outperform Pfizer’s Nurtec
BioSpace
Mon, 06/19/23 - 10:31 am
Eli Lilly
Emgality
Pfizer
Nurtec
migraines
Eli Lilly's Mounjaro is primed to surpass Novo Nordisk's popular diabetes and obesity duo: report
Fierce Pharma
Mon, 06/19/23 - 10:29 am
Eli Lilly
Novo Nordisk
Mounjaro
semaglutide
diabetes
obesity
Eli Lilly CEO says Medicare price negotiations could harm drug development
CNBC
Thu, 06/15/23 - 10:11 am
Inflation Reduction Act
Eli Lilly
Medicare
David Ricks
Pharma CEOs
drug pricing
Eli Lilly’s Mounjaro likely to become ‘leading therapy’ for obesity and type 2 diabetes
Biopharma Reporter
Thu, 06/15/23 - 10:06 am
Eli Lilly
Mounjaro
obesity
type 2 diabetes
Verve partners with Lilly on gene editing therapy for heart disease
BioPharma Dive
Thu, 06/15/23 - 10:02 am
Eli Lilly
Verve Therapeutics
heart disease
gene editing
BIO: Can GLP-1s help you quit smoking or drinking? Lilly is looking into it—cautiously
Fierce Biotech
Fri, 06/9/23 - 11:47 am
BIO 2023
Eli Lilly
GLP-1 agonist
smoking cessation
alcohol-use disorder
Pages
« first
‹ previous
…
5
6
7
8
9
10
11
12
13
…
next ›
last »